title: Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.
abstract: OBJECTIVE
  This randomized double-blind multicenter trial evaluated the effects of olanzapine vs. clozapine on subjective well-being, quality of life (QOL) and clinical outcome.
  
  
  METHODS
  The primary objective was to demonstrate non-inferiority of olanzapine, mean dosage 16.2 +/- 4.8 (5-25 mg/day) vs. clozapine, mean dosage 209 +/- 91 (100-400 mg/day) regarding improvement on the 'Subjective Well-Being under Neuroleptic Treatment' (SWN) Scale after 26 treatment weeks in 114 patients with schizophrenia. Secondary outcome parameters included: Munich QOL Dimension List (MLDL), Positive and Negative Symptom Scale (PANSS), Clinical Global Impression (CGI).
  
  
  RESULTS
  SWN scores improved significantly in both groups, olanzapine was non-inferior to clozapine (group difference 3.2 points in favor of olanzapine; 95% CI: 4.2;10.5). MLDL-satisfaction, PANSS and CGI-S improved similarly, olanzapine yielded a higher CGI Therapeutic Index. Individual SWN and PANSS changes correlated only moderately (r = -0.45).
  
  
  CONCLUSIONS
  Olanzapine was non-inferior to clozapine. The lack of a marked correlation between PANSS and SWN improvements indicates that patients and psychiatrists perceive treatment differently.
authors.affiliation: Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Germany. naber@uke.uni-hamburg.de
authors.forename: D
authors.initials: D
authors.lastname: Naber
authors.forename: M
authors.initials: M
authors.lastname: Riedel
authors.forename: A
authors.initials: A
authors.lastname: Klimke
authors.forename: E-U
authors.initials: EU
authors.lastname: Vorbach
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: K-U
authors.initials: KU
authors.lastname: Kühn
authors.forename: S
authors.initials: S
authors.lastname: Bender
authors.forename: B
authors.initials: B
authors.lastname: Bandelow
authors.forename: W
authors.initials: W
authors.lastname: Lemmer
authors.forename: S
authors.initials: S
authors.lastname: Moritz
authors.forename: R W
authors.initials: RW
authors.lastname: Dittmann
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D003024:Clozapine / Q000008:administration & dosage / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011788:Quality of Life; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine